When looking for stocks that can make one richer, investors often start with names they know. The problem is that the names they know also tend to be the names that everyone knows, and these stocks tend to be valued in such a way that they wouldn't be considered bargains. Voyager Therapeutics (NASDAQ: VYGR) and Zymeworks (NYSE: ZYME) are far from household names, but the two clinical-stage biotech companies could fairly be considered bargains, have already enriched some investors, and they are still at the beginning of their growth cycles.

Voyager focuses on gene therapies to treat central nervous system maladies while Zymeworks specializes in next-generation multifunctional biotherapeutics to treat cancer and other diseases. Both companies have actively pursued collaborative agreements to finance their pipelines, putting them in a better financial situation than many clinical-stage biotechs.

Both companies' shares trade right now for under $10, but I don't expect them to stay there for long considering their growth potential. Let's find out a bit more about these two biotech stocks that could make you richer.

Continue reading

Source Fool.com